[{"id":"fe45fba3-5034-46b7-8f07-75aabce5003c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01841736","created_at":"2023-11-14T21:13:55.188Z","updated_at":"2025-02-25T16:36:15.225Z","phase":"Phase 2","brief_title":"Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors","source_id_and_acronym":"NCT01841736","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 09/20/2013","start_date":" 09/20/2013","primary_txt":" Primary completion: 03/05/2019","primary_completion_date":" 03/05/2019","study_txt":" Completion: 09/13/2025","study_completion_date":" 09/13/2025","last_update_posted":"2025-02-06"},{"id":"829b11a8-2149-49a1-8445-bba09c622fc3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06739395","created_at":"2025-02-26T09:10:09.582Z","updated_at":"2025-02-26T09:10:09.582Z","phase":"Phase 2","brief_title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","source_id_and_acronym":"NCT06739395","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Focus V (anlotinib) • temozolomide • Lenvima (lenvatinib) • Piqray (alpelisib) • pazopanib • Epidaza (chidamide) • Trodelvy (sacituzumab govitecan-hziy) • vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-12-18"},{"id":"7a194544-769d-4908-bc9c-7b8bbff6762b","acronym":"NCI-2012-01247","url":"https://clinicaltrials.gov/study/NCT01684397","created_at":"2023-11-30T22:15:06.234Z","updated_at":"2025-02-25T13:17:55.736Z","phase":"Phase 1/2","brief_title":"Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer","source_id_and_acronym":"NCT01684397 - NCI-2012-01247","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • pazopanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 11/21/2012","start_date":" 11/21/2012","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 05/02/2025","study_completion_date":" 05/02/2025","last_update_posted":"2024-11-06"},{"id":"73bc55f4-9097-42c3-8243-1da98bd3cf4a","acronym":"SPARTO","url":"https://clinicaltrials.gov/study/NCT05210413","created_at":"2022-01-29T18:04:48.446Z","updated_at":"2025-02-25T15:54:20.931Z","phase":"Phase 1/2","brief_title":"Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults","source_id_and_acronym":"NCT05210413 - SPARTO","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" PD-L1 • TMB • MSI","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib • spartalizumab (PDR001)"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 05/17/2022","start_date":" 05/17/2022","primary_txt":" Primary completion: 11/17/2026","primary_completion_date":" 11/17/2026","study_txt":" Completion: 11/17/2027","study_completion_date":" 11/17/2027","last_update_posted":"2024-04-10"},{"id":"23fbfd55-0bea-4321-83e6-d320991b3c5c","acronym":"AMPHISARC","url":"https://clinicaltrials.gov/study/NCT05180695","created_at":"2022-01-06T22:53:30.960Z","updated_at":"2025-02-25T15:54:18.762Z","phase":"Phase 1/2","brief_title":"HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas","source_id_and_acronym":"NCT05180695 - AMPHISARC","lead_sponsor":"Centre Leon Berard","biomarkers":" MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/15/2022","start_date":" 04/15/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-04-08"},{"id":"848154b9-2f4c-4546-93ed-4525fa24f1fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03798106","created_at":"2021-01-18T18:46:40.136Z","updated_at":"2024-07-02T16:35:45.979Z","phase":"Phase 2","brief_title":"A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma","source_id_and_acronym":"NCT03798106","lead_sponsor":"Yonsei University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 04/10/2019","start_date":" 04/10/2019","primary_txt":" Primary completion: 08/10/2022","primary_completion_date":" 08/10/2022","study_txt":" Completion: 08/10/2022","study_completion_date":" 08/10/2022","last_update_posted":"2023-06-12"},{"id":"625426ca-632a-4ebf-9655-292b92e2657f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01430572","created_at":"2021-01-18T05:54:32.973Z","updated_at":"2025-02-25T13:17:05.644Z","phase":"Phase 1","brief_title":"Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients","source_id_and_acronym":"NCT01430572","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/07/2011","start_date":" 10/07/2011","primary_txt":" Primary completion: 05/12/2020","primary_completion_date":" 05/12/2020","study_txt":" Completion: 05/12/2020","study_completion_date":" 05/12/2020","last_update_posted":"2023-06-06"},{"id":"49735e15-4e3d-4d13-9289-8b33e13bc467","acronym":"","url":"https://clinicaltrials.gov/study/NCT02691767","created_at":"2021-03-25T18:46:08.042Z","updated_at":"2024-07-02T16:36:08.681Z","phase":"","brief_title":"Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors","source_id_and_acronym":"NCT02691767","lead_sponsor":"Samsung Medical Center","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 01/16/2018","primary_completion_date":" 01/16/2018","study_txt":" Completion: 02/13/2020","study_completion_date":" 02/13/2020","last_update_posted":"2022-06-15"},{"id":"aec26925-41ed-4f2f-9267-a32e6531e375","acronym":"","url":"https://clinicaltrials.gov/study/NCT02450136","created_at":"2022-06-02T19:55:13.662Z","updated_at":"2024-07-02T16:36:08.673Z","phase":"","brief_title":"Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors","source_id_and_acronym":"NCT02450136","lead_sponsor":"Samsung Medical Center","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 amplification","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 10/08/2015","start_date":" 10/08/2015","primary_txt":" Primary completion: 07/30/2017","primary_completion_date":" 07/30/2017","study_txt":" Completion: 02/01/2018","study_completion_date":" 02/01/2018","last_update_posted":"2022-06-15"},{"id":"192b62b1-c5b0-4b89-a48b-388e2143b71f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01498458","created_at":"2021-01-18T06:17:05.593Z","updated_at":"2024-07-02T16:36:09.126Z","phase":"Phase 1","brief_title":"Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT01498458","lead_sponsor":"German Breast Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 12/01/2011","primary_completion_date":" 12/01/2011","study_txt":" Completion: 05/01/2014","study_completion_date":" 05/01/2014","last_update_posted":"2022-06-10"},{"id":"f824a2d6-2b81-47eb-a411-34718feab175","acronym":"CheckMate 016","url":"https://clinicaltrials.gov/study/NCT01472081","created_at":"2021-01-18T06:08:16.011Z","updated_at":"2024-07-02T16:36:19.911Z","phase":"Phase 1","brief_title":"Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)","source_id_and_acronym":"NCT01472081 - CheckMate 016","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" IL2 • IFNA1","pipe":"","alterations":" ","tags":["IL2 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • sunitinib • pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 194","initiation":"Initiation: 02/09/2012","start_date":" 02/09/2012","primary_txt":" Primary completion: 02/02/2016","primary_completion_date":" 02/02/2016","study_txt":" Completion: 06/03/2021","study_completion_date":" 06/03/2021","last_update_posted":"2021-12-02"},{"id":"006154e1-1580-45ba-ae5b-88d5b8c35fa2","acronym":"BIONIKK","url":"https://clinicaltrials.gov/study/NCT02960906","created_at":"2021-03-03T14:55:07.666Z","updated_at":"2024-07-02T16:36:31.235Z","phase":"Phase 2","brief_title":"A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer","source_id_and_acronym":"NCT02960906 - BIONIKK","lead_sponsor":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","biomarkers":" CD8 • PD-1 • LAG3 • TFE3 • TFEB","pipe":" | ","alterations":" TFEB translocation","tags":["CD8 • PD-1 • LAG3 • TFE3 • TFEB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFEB translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • sunitinib • pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 05/31/2017","start_date":" 05/31/2017","primary_txt":" Primary completion: 02/15/2021","primary_completion_date":" 02/15/2021","study_txt":" Completion: 02/15/2021","study_completion_date":" 02/15/2021","last_update_posted":"2021-04-26"},{"id":"a118f1a6-12e8-4f43-a37c-f523fc0659ee","acronym":"OVAR16","url":"https://clinicaltrials.gov/study/NCT00866697","created_at":"2021-02-16T16:52:14.245Z","updated_at":"2025-02-25T13:14:47.821Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT00866697 - OVAR16","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 940","initiation":"Initiation: 05/26/2009","start_date":" 05/26/2009","primary_txt":" Primary completion: 07/08/2012","primary_completion_date":" 07/08/2012","study_txt":" Completion: 08/24/2017","study_completion_date":" 08/24/2017","last_update_posted":"2021-02-16"},{"id":"931a0803-d4c8-4f98-9bb6-97e87c40e482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01956669","created_at":"2021-01-18T08:52:55.254Z","updated_at":"2024-07-02T16:36:42.063Z","phase":"Phase 2","brief_title":"Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors","source_id_and_acronym":"NCT01956669","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KIT • KDR • AFP • FLT1 • VEGFC • FGF","pipe":"","alterations":" ","tags":["KIT • KDR • AFP • FLT1 • VEGFC • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 10/08/2014","start_date":" 10/08/2014","primary_txt":" Primary completion: 11/05/2019","primary_completion_date":" 11/05/2019","study_txt":" Completion: 11/05/2019","study_completion_date":" 11/05/2019","last_update_posted":"2020-08-12"},{"id":"f1d09afa-0b3f-47aa-b79e-43886e135f29","acronym":"","url":"https://clinicaltrials.gov/study/NCT01466972","created_at":"2021-01-17T17:34:24.702Z","updated_at":"2025-02-25T13:17:16.037Z","phase":"Phase 2","brief_title":"Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib","source_id_and_acronym":"NCT01466972","lead_sponsor":"Hope Rugo, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 04/27/2012","start_date":" 04/27/2012","primary_txt":" Primary completion: 12/07/2015","primary_completion_date":" 12/07/2015","study_txt":" Completion: 10/02/2019","study_completion_date":" 10/02/2019","last_update_posted":"2020-07-08"},{"id":"c9a4cec3-a91c-4bce-b61e-71cb0817eced","acronym":"","url":"https://clinicaltrials.gov/study/NCT01975519","created_at":"2021-01-18T08:59:39.076Z","updated_at":"2024-07-02T16:36:44.893Z","phase":"Phase 2a","brief_title":"A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT01975519","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 12/10/2013","start_date":" 12/10/2013","primary_txt":" Primary completion: 03/11/2019","primary_completion_date":" 03/11/2019","study_txt":" Completion: 03/11/2019","study_completion_date":" 03/11/2019","last_update_posted":"2020-05-20"},{"id":"9b88c18b-5dbc-410e-baed-d090e5a3cd6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01446809","created_at":"2021-01-18T06:00:08.601Z","updated_at":"2024-07-02T16:36:46.074Z","phase":"","brief_title":"Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma","source_id_and_acronym":"NCT01446809","lead_sponsor":"University of Washington","biomarkers":" KDR","pipe":"","alterations":" ","tags":["KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • pazopanib • cyclophosphamide • ifosfamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2020-04-13"},{"id":"fc6716ed-3150-4253-b2cb-bb463accc6ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT00454363","created_at":"2021-01-18T01:36:39.054Z","updated_at":"2024-07-02T16:36:46.700Z","phase":"Phase 2","brief_title":"Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer","source_id_and_acronym":"NCT00454363","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • ABL1","pipe":"","alterations":" ","tags":["EGFR • ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 03/01/2007","start_date":" 03/01/2007","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2020-04-03"},{"id":"f1227737-a814-4556-a309-6f9739ca08f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01832259","created_at":"2021-01-18T08:09:04.311Z","updated_at":"2025-02-25T15:40:48.575Z","phase":"Phase 2","brief_title":"A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection","source_id_and_acronym":"NCT01832259","lead_sponsor":"University of Utah","biomarkers":" VEGFA • FLT1","pipe":"","alterations":" ","tags":["VEGFA • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 02/07/2017","primary_completion_date":" 02/07/2017","study_txt":" Completion: 08/09/2018","study_completion_date":" 08/09/2018","last_update_posted":"2018-12-12"},{"id":"c31c614d-4f6e-42bf-9ed7-7a257d1cea09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00509587","created_at":"2021-01-18T01:49:58.524Z","updated_at":"2024-07-02T16:37:08.134Z","phase":"Phase 2","brief_title":"Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT00509587","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 07/01/2009","primary_completion_date":" 07/01/2009","study_txt":" Completion: 08/01/2013","study_completion_date":" 08/01/2013","last_update_posted":"2018-08-08"},{"id":"ada2d6a5-f97c-4c3f-8822-f9c8edd72568","acronym":"","url":"https://clinicaltrials.gov/study/NCT00615524","created_at":"2021-01-18T02:17:13.090Z","updated_at":"2024-07-02T16:37:14.903Z","phase":"Phase 2","brief_title":"Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer","source_id_and_acronym":"NCT00615524","lead_sponsor":"GlaxoSmithKline","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib • exemestane"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2008","start_date":" 04/01/2008","primary_txt":" Primary completion: 11/01/2012","primary_completion_date":" 11/01/2012","study_txt":" Completion: 11/01/2012","study_completion_date":" 11/01/2012","last_update_posted":"2018-01-12"},{"id":"8e0ebdcb-d269-40d1-b79d-6909b3b09c89","acronym":"","url":"https://clinicaltrials.gov/study/NCT00370513","created_at":"2021-01-18T01:17:12.862Z","updated_at":"2024-07-02T16:37:16.311Z","phase":"Phase 1","brief_title":"A Phase I Study of Pazopanib in Adult Patients With Liver Cancer","source_id_and_acronym":"NCT00370513","lead_sponsor":"GlaxoSmithKline","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 12/06/2006","start_date":" 12/06/2006","primary_txt":" Primary completion: 04/08/2009","primary_completion_date":" 04/08/2009","study_txt":" Completion: 04/08/2009","study_completion_date":" 04/08/2009","last_update_posted":"2017-11-17"},{"id":"d8e80a7c-878b-4b80-98fe-b5b845801b82","acronym":"","url":"https://clinicaltrials.gov/study/NCT00619424","created_at":"2021-01-18T02:18:08.617Z","updated_at":"2024-07-02T16:37:16.294Z","phase":"Phase 1","brief_title":"A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT00619424","lead_sponsor":"GlaxoSmithKline","biomarkers":" IL10","pipe":"","alterations":" ","tags":["IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • pazopanib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 11/15/2007","start_date":" 11/15/2007","primary_txt":" Primary completion: 09/04/2009","primary_completion_date":" 09/04/2009","study_txt":" Completion: 09/04/2009","study_completion_date":" 09/04/2009","last_update_posted":"2017-11-17"},{"id":"ad9d6981-8a33-4e37-a0e4-47363ebe3ed6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00678977","created_at":"2021-01-18T02:32:17.325Z","updated_at":"2024-07-02T16:37:16.381Z","phase":"Phase 1","brief_title":"A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors","source_id_and_acronym":"NCT00678977","lead_sponsor":"GlaxoSmithKline","biomarkers":" IL2 • IL10","pipe":"","alterations":" ","tags":["IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 04/03/2008","start_date":" 04/03/2008","primary_txt":" Primary completion: 03/30/2010","primary_completion_date":" 03/30/2010","study_txt":" Completion: 06/30/2011","study_completion_date":" 06/30/2011","last_update_posted":"2017-11-14"}]